A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
Reported herein are two endoscopic studies performed to compare the gastrointestinal mucosal effects of encapsulated enteric-coated aspirin granules with several other well-known aspirin products. The first study compared the effects of Ascriptin A/D, Bayer, Bufferin, and 325 mg enteric-coated aspirin granules (325 mg Ecotrin capsules); the second study compared Anacin Arthritis Pain Formula, Arthritis Strength Bufferin, Ascriptin A/D, Bayer, and 500 mg enteric-coated aspirin granules (500 mg Ecotrin capsule). In both of these studies the Ecotrin capsule induced less stomach damage than did any of the other aspirin products tested. The Ecotrin capsule was also shown to cause less damage to the proximal duodenum than did Bayer.
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002021:Buffers; D004386:Duodenum / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D013270:Stomach / Q000187:drug effects; D013608:Tablets, Enteric-Coated; D013997:Time Factors
D002021:Buffers; D013608:Tablets, Enteric-Coated; D001241:Aspirin